Skip to main content
VERTEX PHARMACEUTICALS INC / MA logo

VERTEX PHARMACEUTICALS INC / MA — Investor Relations & Filings

Ticker · VRTX ISIN · US92532F1003 LEI · 54930015RAQRRZ5ZGJ91 US Manufacturing
Filings indexed 2,379 across all filing types
Latest filing 2023-05-01 Director's Dealing
Country US United States of America
Listing US VRTX

About VERTEX PHARMACEUTICALS INC / MA

https://www.vrtx.com/

Vertex Pharmaceuticals is a global biotechnology company that invests in scientific innovation to discover, develop, and commercialize transformative medicines for serious diseases. The company is a leader in the field of cystic fibrosis (CF), having developed multiple therapies that treat the underlying cause of the disease for a significant portion of patients. Beyond its focus on CF, Vertex is advancing a research and development pipeline that includes potential treatments for other serious conditions such as sickle cell disease, beta-thalassemia, APOL1-mediated kidney disease, acute and neuropathic pain, and type 1 diabetes. The company's strategy is centered on a deep understanding of human biology to address the root cause of illness.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-05-01 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 1, 2023, reporting the company's consolidated financial results for the quarter ended March 31, 2023. It specifically states that the financial results are provided via a press release attached as Exhibit 99.1. The text indicates this is a current report announcing earnings results rather than the full earnings release document itself. The document length is 3575 characters, which is relatively short and mainly serves as an announcement of the earnings results with a press release attached. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2023-05-01 English
Regulatory Filings 2023
Regulatory Filings
2023-04-27 English
FORM 4 SUBMISSION
Director's Dealing
2023-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2023-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2023-04-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.